Boston, MA (September 30, 2002) Delegates attending the 7th International Conference on Geriatric Oncology reviewed data on the special treatment needs of elderly cancer patients. The data is relevant given the increased organ impairment (e.g. increased cardiovascular disease), and the increasing trend for multiple drug consumption ("poly-pharmacy") in the elderly cancer patient. Clinical trial experts say the potential risks to the elderly patient are underestimated due to restrictive clinical trial entry requirements.
Use of granisetron, an antiemetic drug with no cardiovascular restrictions and low potential for drug interactions is an appropriate choice for elderly cancer patients because granisetron is unlikely to create additional complications.
Antiemetics are used to treat chemotherapy and radiation therapy induced nausea and vomiting. Of the antiemetics, the 5HT3 receptor antagonists, like granisetron, are considered the gold standard in treatment and have a good tolerability and safety profile, particularly when compared to the other older antiemetics.
Differences, however, have been noted within the 5HT3 class in relation to the potential for cardiovascular toxicity and potential for adverse drug interactions.
Commenting on the cardiovascular risks from antiemetic therapy, Dr. Matti Aapro (Clinique de Genolier, Genolier, Switzerland) said, "The increased incidence of cardiovascular disease seen with increasing age necessitates careful consideration of the potential cardiotoxic properties of treatments."
"The increased risk from repeat cardiovascular insult in elderly patients with cardiovascular impairment is unknown, but the risk likely exists," said Dr. Aapro regarding clinical implications. "The cardiovascular side effect profile of antiemetics should be a key consideration in the elderly population and clinicians should be selecting the antiemetic with the lowest risk potential," he added.
Page: 1 2 Related medicine news :1
Contact: Whitney Hartmann
Shire Health New York
. Experts debate benefits, dangers of chlorine in C&EN point-counterpoint2
. Experts to discuss new advances in IBS therapy and its affect on IBS sufferers3
. Experts to discuss emerging technologies in GI diagnosis and treatment4
. Experts to discuss the affects of non-steroidal anti-inflammatory drugs (NSAIDs)5
. Experts present new research on the hot topics of aging at GSAs Annual Meeting6
. Experts welcome major reforms to the coroners service7
. Experts meet to challenge approaches of testing and developing cancer treatments8
. Experts gathering to discuss tapping into $40-$50 billion natural products market9
. Experts recommend increased funding, focus on resuscitation science10
. Experts announce global antimicrobial resistance initiative - World preview of the Global White Paper on bacterial resistance in respiratory tract infections - a call for concerted international action11
. Heart Experts Call For Action Against Missed Opportunities To Prevent Heart Disease In Women